热门资讯> 正文
Klotho Neurosciences将收购Turn Biotechnologies的精选资产
2025-09-30 21:25
- Klotho Neurosciences (NASDAQ:KLTO) said on Tuesday that it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies.
- Under the LOI, Klotho would acquire Turn's ERA ("Epigenetic Reprogramming of Age") platform and eTurna RNA delivery system.
- Importantly, as part of this transaction, Klotho will be acquiring a signed out-licensing and co-development partnership with one of South Korea's leading pharmaceutical companies worth up to $300 million.
More on Klotho Neurosciences, Inc.
- Financial information for Klotho Neurosciences, Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
